Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. - Test2 - elhamkhani - TriplyDB

Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria.

Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria.

http://www.wikidata.org/entity/Q33298467

about

Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization Malaria Distribution, Prevalence, Drug Resistance and Control in Indonesia Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis.Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria.Resistance to therapies for infection by Plasmodium vivax Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis.Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.Update on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria.Randomized comparison of the efficacies and tolerabilities of three artemisinin-based combination treatments for children with acute Plasmodium falciparum malaria in the Democratic Republic of the Congo.Population Pharmacokinetics and Antimalarial Pharmacodynamics of Piperaquine in Patients With Plasmodium vivax Malaria in Thailand Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania.Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.Implementation of a reference standard and proficiency testing programme by the World Wide Antimalarial Resistance Network (WWARN)Efficacy and safety of fixed dose combination of arterolane maleate and piperaquine phosphate dispersible tablets in paediatric patients with acute uncomplicated Plasmodium falciparum malaria: a phase II, multicentric, open-label study.Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome.Effect of nutritional status on response to treatment with artemisinin-based combination therapy in young Ugandan children with malaria Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants Artemisinin combination therapy: a good antimalarial, but is the dose right?Pharmacokinetic-pharmacodynamic analysis of spiroindolone analogs and KAE609 in a murine malaria model.A small amount of fat does not affect piperaquine exposure in patients with malaria.Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria.Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum.Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso Rethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study.Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria.Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border.The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam.Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010.A Phase 3, Double-Blind, Randomized Study of Arterolane Maleate-Piperaquine Phosphate vs Artemether-Lumefantrine for Falciparum Malaria in Adolescent and Adult Patients in Asia and Africa Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria.Piperaquine pharmacodynamics and parasite viability in a murine malaria model.Failure of dihydroartemisinin plus piperaquine treatment of falciparum malaria by under-dosing in an overweight patient.Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria.Introducing New Antimalarial Analogues of Chloroquine and Amodiaquine: A Narrative Review.Improving the role and contribution of pharmacokinetic analyses in antimalarial drug clinical trials.

P2860

Q24202910-4A4EACF4-6BDF-4E16-93BD-5482C9A1A3CB Q24235351-0C1DB437-B846-4732-B73A-B6CE58D4FA45 Q26822489-FD445277-0B9A-4F77-AABC-A4D937F48B3D Q26830528-3450B2CC-23A9-4E98-B193-3E21BE9C6745 Q29306432-AB40BB81-C287-4F69-84F3-7FDC4AA61710 Q31153944-20E3B5A4-2099-4584-B464-F039E55AE256 Q33385477-B5B7A50C-6E6A-4FF0-A86B-D5BF966447D9 Q33481576-33C7DFFA-D61B-478E-9874-682DB66379FE Q33489551-060A1942-EEDB-41AF-B6FA-C48F77C2FCD9 Q33516563-D522A550-0358-491B-BCDA-FD0263C035ED Q33635019-F17E92E3-D30F-4E5E-9FC2-BFEE34D34494 Q34057403-5D44C8A0-3DCE-4A4C-87F4-282F14D52CA9 Q34116219-2CBFE4B6-F324-4B28-8397-587CA770327C Q34227179-6933BF7B-1D5E-4981-BED6-A07ACB565D1F Q34299078-F0BBE386-F1FE-4EC3-AF8F-3EED09887C33 Q34485984-281F418B-D748-42EE-A009-5AE20DFBB2FB Q34503134-569BED66-D070-46C8-93AD-ABB1E675B8DF Q34737444-1BD50CB7-1630-4421-87B4-7B4C5B13D004 Q35004867-9DF99934-B6D8-4CE3-8EBC-C7F636B72A63 Q35055212-557D063A-A2C9-4193-944D-DF9BED9A5717 Q35069127-A23FDE50-1070-494C-B0A0-BBB90ABFA369 Q35105913-AD5DA864-89CD-4F9E-98F7-298EA3E4159E Q35191426-B2B69518-CEBC-4FBF-921A-4807B4BAB0F1 Q35598379-45DA37C5-6FA5-4A0F-97ED-1C0D9937EF82 Q35834198-9A863356-CD02-41BE-993D-A5A198338D1E Q35859839-669719C7-FCA5-41B8-9945-5C7EB0107F63 Q35859844-B3E3D5A0-C234-4882-804A-E81C59F2696A Q36018444-5F5459F8-0830-4DD8-A628-8158F9E6B436 Q36018642-2B564CC9-70E3-4033-994C-AFDE3A6B4E93 Q36075976-6309CFF2-FFAC-4DF9-877E-FDB9E4A5C245 Q36138872-C91B0089-3DC7-4507-82C1-AB01D6C1BE0D Q36482878-7E7BB506-ADE8-485D-8314-735C84D7F873 Q36558557-48E6E4B3-B04F-4D22-A073-304EEFCC9A2D Q36715829-C8BA0197-F371-48F8-93A3-186752B851B9 Q37077284-A4C75D64-0204-442B-B60E-A7E67393877A Q37247580-1C48F639-C0AA-46D4-97C4-0CB5DCE47CEB Q37267688-A4C835C1-4133-467B-AC7A-24EB2ACF682D Q37383670-F6F5241E-6CAF-41EE-A1FA-7A355C00AC24 Q37721293-6C7B21FB-80A2-423A-9540-4D52F4AEA501 Q38225084-CCBB0145-9B44-48EF-BD25-0E9C92359FD6

P2860

Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria.

http://www.wikidata.org/entity/Q33298467

description

2007 nî lūn-bûn

@nan

2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Clinical and pharmacological d ...... ne for drug-resistant malaria.

@ast

Clinical and pharmacological d ...... ne for drug-resistant malaria.

@en

Clinical and pharmacological d ...... ne for drug-resistant malaria.

@nl

type

label

Clinical and pharmacological d ...... ne for drug-resistant malaria.

@ast

Clinical and pharmacological d ...... ne for drug-resistant malaria.

@en

Clinical and pharmacological d ...... ne for drug-resistant malaria.

@nl

prefLabel

Clinical and pharmacological d ...... ne for drug-resistant malaria.

@ast

Clinical and pharmacological d ...... ne for drug-resistant malaria.

@en

Clinical and pharmacological d ...... ne for drug-resistant malaria.

@nl

P1433

Q33298467-65520E5A-741D-4B99-AEF9-C8108DE030FD

P1476

Q33298467-A5FFD506-73B0-46C9-8D33-959A8C3BDD6F

P2093

Q33298467-06BE4BFF-D794-44FF-8927-B9D4928EA879

Q33298467-192D34BA-D180-49EE-B7F6-DBF47F26685C

Q33298467-2C47F8B1-5907-4ADE-AC14-5F0A0C2126D2

Q33298467-3C26B191-3FC1-42ED-B23B-AD96DD024AEB

Q33298467-44B3D270-53A1-456D-BA0D-640B06C1DF68

Q33298467-57C6E41D-1D1A-4B6F-8B8E-4602749D805F

Q33298467-8FD3702E-1CEE-4C45-B8E0-4FF752EF4097

Q33298467-9E7308BB-6C87-4683-8DAE-850195A1E2FE

Q33298467-FCE2EB89-AE01-4FCE-90D2-802D15DE6A2A

P2860

Q33298467-0998B95C-7750-4A9C-BD63-4F1F780AD2C7

Q33298467-1C742A66-7B04-42F0-BE0A-624E2D3F1ECB

Q33298467-1D07D8A0-7352-43CD-AC62-4B915CE97414

Q33298467-1E776B30-833D-4DC6-B049-B4CCBCAAEE9E

Q33298467-26D46173-7101-4908-A9A7-AF5A5061AD8A

Q33298467-47157290-E723-4C00-B5D3-8588288B179C

Q33298467-60D98E40-AA6C-44DE-A9EE-48A7CF529827

Q33298467-7A6868CE-262D-46B1-808E-4009BFC53ABC

Q33298467-88CFC137-7164-4F1B-8530-7154799FC562

Q33298467-8D2F410C-7F51-4102-A0C5-32B6CFC06DCE

P304

Q33298467-C88D5D1F-5AD2-402A-9133-D0571CFECC1B

P31

Q33298467-FB2577D9-92D7-458B-9356-CD34222D9897

P356

Q33298467-5C21FC77-C296-4B29-B7D5-42DA2892F0A2

P407

Q33298467-F0B8E4E4-0DB7-4B0E-8342-5088DEDEF8D7

P433

Q33298467-C4C91AC2-6EC8-4236-A653-BDE2C75B20A5

P478

Q33298467-42B17986-7E57-4483-B388-A12BA5C3F267

P50

Q33298467-92A4E06A-CB81-41AB-8A5D-7E408D149605

Q33298467-A78EC46F-7268-4010-9C84-F3DCD0CED9BD

Q33298467-B8FC50CF-8B50-4F16-9F0E-FD9CD2E10182

P577

Q33298467-531A8FDD-4CDC-40D9-BEF3-732A81924DE4

P698

Q33298467-36D4F8BA-CE54-483A-81FA-77450652993C

P921

Q33298467-658C10DD-EE11-4C37-A624-0ADE86B203FB

Q33298467-F960B721-7B4C-4055-B0BB-FF9024AEFCFE

P932

Q33298467-EA259E67-8EE6-405A-AE41-C2A3814CE1EF

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Clinical and pharmacological d ...... ne for drug-resistant malaria.

@en

P2093

A R Hasugian

http://www.w3.org/2001/XMLSchema#string

A Ratcliff

http://www.w3.org/2001/XMLSchema#string

E Kenangalem

http://www.w3.org/2001/XMLSchema#string

E P Ebsworth

http://www.w3.org/2001/XMLSchema#string

E Tjitra

http://www.w3.org/2001/XMLSchema#string

F Laihad

http://www.w3.org/2001/XMLSchema#string

H L E Purba

http://www.w3.org/2001/XMLSchema#string

H Siswantoro

http://www.w3.org/2001/XMLSchema#string

N Lindegardh

http://www.w3.org/2001/XMLSchema#string

P2860

The global distribution of clinical episodes of Plasmodium falciparum malaria

Vivax malaria: neglected and not benign

Artesunate and dihydroartemisinin (DHA): unusual decomposition products formed under mild conditions and comments on the fitness of DHA as an antimalarial drug.

Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia.

Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison.

Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria.

Effects of a high-fat meal on the relative oral bioavailability of piperaquine

Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria.

Piperaquine: a resurgent antimalarial drug.

The assessment of antimalarial drug efficacy.

P304

4090-4097

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00486-07

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

Pasi M Penttinen

Nicholas M Anstey

P577

2007-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17846129

http://www.w3.org/2001/XMLSchema#string

P921

P932

2151469

http://www.w3.org/2001/XMLSchema#string